Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 7.1% in the afternoon session after the company trimmed the upper ...

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

We may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...

Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.

An mRNA cancer vaccine triggered strong immune responses and improved treatment outcomes in mice, offering a new approach to ...

A nationwide Danish cohort study demonstrated no increased risk of serious adverse events following vaccination with JN.1-updated mRNA COVID-19 vaccines, reinforcing their safety profile and ...

Researchers found that the stereochemistry of lipids like ALC-315 affects mRNA drug safety and efficacy, offering a path to ...

A new study details a way to selectively route mRNA to the pancreas by using the body’s own endogenous pathways – systems ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have ...

A gene known as PSAT1, delivered through synthetic modified messenger RNA, can stimulate heart muscle repair and improve ...